NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
NextCure, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.67−0.57 (-9.13%)
Close on Oct 19, 2026
- Market cap
- $30.11M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
NextCure statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | NextCure | Industry median |
|---|---|---|
| Market Cap | $25.95M | $166.30M |
| Enterprise Value | $10.69M | $88.19M |
| PB Ratio | 2.14 | 2.03 |
| P/TBV Ratio | 2.14 | 2.29 |
Income (trailing twelve months)
| Measure | NextCure | Industry median |
|---|---|---|
| Operating Income | -$43.90M | -$21.40M |
| Net Income | -$42.75M | -$22.46M |
| EBITDA | -$43.90M | -$16.91M |
| EPS (Diluted) | -$10.26 | -$0.83 |
Returns
| Measure | NextCure | Industry median |
|---|---|---|
| Return on Equity (ROE) | -204.6% | -53.2% |
| Return on Assets (ROA) | -121.6% | -40.9% |
| Return on Invested Capital (ROIC) | -320.5% | -32.4% |
| Return on Capital Employed (ROCE) | -270.9% | -38.1% |
Balance sheet
| Measure | NextCure | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $15.26M | $61.43M |
| Net Cash (Debt) | $15.26M | $15.35M |
| Net Cash Per Share | $3.33 | $0.66 |
| Equity (Book Value) | $12.15M | $49.09M |
| Book Value Per Share | $2.65 | $1.37 |
| Tangible Book Value | $12.15M | $23.52M |
| Working Capital | $15.84M | $76.81M |
Financial position
| Measure | NextCure | Industry median |
|---|---|---|
| Current Ratio | 3.47 | 3.34 |
| Quick Ratio | 2.38 | 2.44 |
Cash flow (trailing twelve months)
| Measure | NextCure | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.98M | -$12.35M |
Efficiency
| Measure | NextCure | Industry median |
|---|---|---|
| Profits Per Employee | -$1.07M | -$703.34K |
| Employee Count | 40 | 74 |
Dividends and yields
| Measure | NextCure | Industry median |
|---|---|---|
| Earnings Yield | -164.7% | -23.3% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | NextCure | Industry median |
|---|---|---|
| Shares Outstanding | 4,577,360 | 58,127,000 |
| Shares Change (YoY) | 83.6% | 10.9% |
| Shares Change (QoQ) | 12.8% | 0.54% |
| Float | 3,530,620 | 49,136,700 |
| Shares Held by Insiders | 22.9% | 11.6% |
| Shares Held by Institutions | 37.9% | 59.4% |
Taxes
| Measure | NextCure | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | NextCure | Industry median |
|---|---|---|
| Altman Z-Score | -32.59 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from NextCure's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.